Cataract Formation in a Child Receiving Dabrafenib and Trametinib Therapy.

IF 1 4区医学 Q4 OPHTHALMOLOGY

Journal of Pediatric Ophthalmology & Strabismus Pub Date : 2024-09-01 DOI:10.3928/01913913-20240722-01

Elaine Botros, Yasmin Bradfield, Nicholas Pytel

引用次数: 0

Abstract

The authors report a case of bilateral cataract in a 9-year-old girl after being treated with a combination of the targeted therapy drugs dabrafenib and trametinib. Although adverse effects have been reported with this treatment, this report is the first documented case of cataract as a complication. [J Pediatr Ophthalmol Strabismus. 2024;61(5):e47-e49.].

查看原文本刊更多论文

接受达拉非尼和曲美替尼治疗的儿童白内障形成。

作者报告了一例9岁女孩在接受靶向治疗药物达拉非尼和曲美替尼的联合治疗后出现双侧白内障的病例。虽然这种疗法的不良反应已有报道，但本报告是首例白内障并发症的记录病例。[2024;61(5):e47-e49.].

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pediatric Ophthalmology & Strabismus 医学-小儿科

CiteScore

1.80

自引率

8.30%

发文量

115

审稿时长

>12 weeks

期刊介绍： The Journal of Pediatric Ophthalmology & Strabismus is a bimonthly peer-reviewed publication for pediatric ophthalmologists. The Journal has published original articles on the diagnosis, treatment, and prevention of eye disorders in the pediatric age group and the treatment of strabismus in all age groups for over 50 years.